60
Participants
Start Date
November 9, 2021
Primary Completion Date
July 15, 2022
Study Completion Date
August 24, 2022
NNC0385-0434 A 100 mg
All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
Novo Nordisk Investigational Site, Berlin
Lead Sponsor
Novo Nordisk A/S
INDUSTRY